DK0858337T3 - Farmaceutisk præparat til behandling af autoimmune sygdomme - Google Patents

Farmaceutisk præparat til behandling af autoimmune sygdomme

Info

Publication number
DK0858337T3
DK0858337T3 DK96937258T DK96937258T DK0858337T3 DK 0858337 T3 DK0858337 T3 DK 0858337T3 DK 96937258 T DK96937258 T DK 96937258T DK 96937258 T DK96937258 T DK 96937258T DK 0858337 T3 DK0858337 T3 DK 0858337T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
pct
treatment
autoimmune diseases
date
Prior art date
Application number
DK96937258T
Other languages
Danish (da)
English (en)
Inventor
Angelo Guglielmotti
Paolo Dionisio
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11372453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0858337(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acraf filed Critical Acraf
Application granted granted Critical
Publication of DK0858337T3 publication Critical patent/DK0858337T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
DK96937258T 1995-10-31 1996-10-26 Farmaceutisk præparat til behandling af autoimmune sygdomme DK0858337T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT95MI002242A IT1276031B1 (it) 1995-10-31 1995-10-31 Composizione farmaceutica per il trattamento delle malattie autoimmuni

Publications (1)

Publication Number Publication Date
DK0858337T3 true DK0858337T3 (da) 2006-09-18

Family

ID=11372453

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96937258T DK0858337T3 (da) 1995-10-31 1996-10-26 Farmaceutisk præparat til behandling af autoimmune sygdomme

Country Status (27)

Country Link
US (1) US6020356A (pl)
EP (1) EP0858337B1 (pl)
JP (1) JP4007615B2 (pl)
KR (1) KR19990067237A (pl)
CN (1) CN1229113C (pl)
AT (1) ATE326965T1 (pl)
AU (1) AU721841B2 (pl)
BR (1) BR9611320B1 (pl)
CA (1) CA2236256C (pl)
CZ (1) CZ292258B6 (pl)
DE (1) DE69636167T2 (pl)
DK (1) DK0858337T3 (pl)
EA (1) EA000826B1 (pl)
ES (1) ES2264144T3 (pl)
HK (1) HK1018219A1 (pl)
HU (1) HU228051B1 (pl)
IL (1) IL124291A (pl)
IT (1) IT1276031B1 (pl)
MX (1) MX9803478A (pl)
NO (1) NO324130B1 (pl)
NZ (1) NZ321580A (pl)
PL (1) PL186377B1 (pl)
PT (1) PT858337E (pl)
SK (1) SK284069B6 (pl)
TR (1) TR199800765T2 (pl)
WO (1) WO1997016185A2 (pl)
ZA (1) ZA969060B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
IT1293795B1 (it) 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
ES2335008T3 (es) * 2003-04-24 2010-03-18 Jagotec Ag Comprimido con nucleo coloreado.
ES2400446T5 (es) 2006-08-03 2017-03-13 Horizon Pharma Ag Tratamiento con glucocorticoides de liberación retardada de una enfermedad reumática
ITMI20062254A1 (it) * 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
EP2391369A1 (en) * 2009-01-26 2011-12-07 Nitec Pharma AG Delayed-release glucocorticoid treatment of asthma
BR112012002130A2 (pt) 2009-08-03 2015-09-15 Aziende Chimique Riunite Angelini Francesco A C R A F S P A processo para a preparação de composto,e, composto intermediário
UA108742C2 (uk) * 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
US8999292B2 (en) * 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
AU2013255050B2 (en) * 2012-05-01 2016-07-28 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
CA3144861A1 (en) 2019-06-25 2020-12-30 Translatum Medicus, Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04506066A (ja) * 1989-06-16 1992-10-22 ジ・アップジョン・カンパニー 脈管形成を抑制するためのスラミン・タイプの化合物および脈管形成抑止ステロイド類
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
US5770589A (en) * 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
AU7376494A (en) * 1993-08-04 1995-02-28 Andrulis Pharmaceuticals Corporation Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents
US5434170A (en) * 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
EP0827404A1 (en) * 1995-05-10 1998-03-11 Pfizer Inc. Combination of methotrexate and tenidap for the treatment of rheumatoid arthritis

Also Published As

Publication number Publication date
ITMI952242A0 (pl) 1995-10-31
BR9611320B1 (pt) 2010-08-10
US6020356A (en) 2000-02-01
JP4007615B2 (ja) 2007-11-14
NO981951D0 (no) 1998-04-29
CA2236256C (en) 2005-02-22
EA000826B1 (ru) 2000-04-24
ITMI952242A1 (it) 1997-05-01
EA199800417A1 (ru) 1998-10-29
NO981951L (no) 1998-06-29
HK1018219A1 (en) 1999-12-17
PL186377B1 (pl) 2003-12-31
PT858337E (pt) 2006-09-29
WO1997016185A2 (en) 1997-05-09
AU721841B2 (en) 2000-07-13
CZ132698A3 (cs) 1998-10-14
HUP9901303A3 (en) 2001-04-28
DE69636167T2 (de) 2007-03-29
NO324130B1 (no) 2007-09-03
KR19990067237A (ko) 1999-08-16
CZ292258B6 (cs) 2003-08-13
SK284069B6 (sk) 2004-09-08
CN1229113C (zh) 2005-11-30
CN1207042A (zh) 1999-02-03
EP0858337A2 (en) 1998-08-19
ATE326965T1 (de) 2006-06-15
ES2264144T3 (es) 2006-12-16
HUP9901303A2 (hu) 1999-09-28
AU7493896A (en) 1997-05-22
ZA969060B (en) 1997-05-29
JPH11515020A (ja) 1999-12-21
MX9803478A (es) 1998-11-30
PL326371A1 (en) 1998-09-14
CA2236256A1 (en) 1997-05-09
NZ321580A (en) 2000-02-28
WO1997016185A3 (en) 1997-07-03
EP0858337B1 (en) 2006-05-24
SK57998A3 (en) 1998-12-02
DE69636167D1 (de) 2006-06-29
TR199800765T2 (xx) 1998-08-21
IT1276031B1 (it) 1997-10-24
IL124291A (en) 2001-06-14
HU228051B1 (en) 2012-09-28
BR9611320A (pt) 1999-03-02

Similar Documents

Publication Publication Date Title
BG104620A (en) Oral pharmaceutical extended release dosage form
DK0713490T3 (da) Ringstabiliserede rapamycinderivater
NO995006D0 (no) Nye forbindelser
DK0703786T3 (da) Anvendelse af nona- og dekapeptider til fremstilling af et lægemiddel til behandling af AIDS
DK1293207T3 (da) Anvendelse af ritonavir (ABT-538) til forbedring af farmokokinetikken af lægemidler, som metaboliseres af cytochrome P450 i en fremgangsmåde til at behandle AIDS
DK1014966T3 (da) Farmaceutisk præparat til behandling af neurologiske og neuropsykiatriske lidelser
CY1107465T1 (el) Μελαγατρανη για τη θepαπευτικη αντιμετωπιση φλεγμονων
DK0858337T3 (da) Farmaceutisk præparat til behandling af autoimmune sygdomme
PT921787E (pt) Regime de administracao de inibidores de atpase de h',k'
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
ATE319715T1 (de) Antikonvulsive pseudofructopyranose sulfamate
ATE235901T1 (de) Pharmazeutische zusammensetzung enthaltend 3-(2,2,2-trimethylhydrazinium)proprionat und gamma- butyrobetain für die behandlung von herz-gefäss- erkrankungen
GEP20063719B (en) Prevention of Migraine Recurrence
ES2172182T3 (es) Composiciones farmaceuticas que comprenden cefuroxima axetil.
SE9302218D0 (sv) New use
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
WO1998038986A3 (en) Use of carvedilol or derivatives thereof for the manufacture of a medicament for the prevention and treatment of viral infections
WO1998038985A3 (en) Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases
MX9706825A (es) El uso farmacologico de ciertos derivados de cistina.